Sudhanshu Vrati

RCB, Faridabad

Dr. Sudhanshu Vrati is working at the Regional Centre for Biotechnology (RCB), first as its Executive Director (2016–2023) and currently as a JC Bose National Fellow of the Anusandhan National Research Foundation (ANRF), and the Emeritus Scientist of the Indian Council of Medical Research (ICMR). Dr Vrati’s research has focused on understanding RNA virus replication and designing anti-virals and vaccine candidates against Japanese encephalitis (JE) and rotaviral diarrhea. Dr Vrati is a fellow of the Indian National Science Academy (INSA), the National Academy of Sciences, India (NASI), and the Indian Academy of Science (IASc). He has received several awards including the prestigious National Bioscience Award and the Tata Innovation Fellowship from the Department of Biotechnology, Govt. of India.

Sudhanshu Vrati

2C- Special Session on Public Health

Chairperson: Saumitra Das, IISc, Bengaluru

Chikungunya Virus: a Major Emerging and Re-emerging Virus

Chikungunya virus (CHIKV), a mosquito-borne alphavirus transmitted by Aedes mosquitoes, has emerged as a major global public-health threat. First identified in Tanzania in 1952, CHIKV now affects 119 countries, causing more than one million infections annually. Although fever and rash usually resolve within days, persistent and debilitating joint pain can cause long-term morbidity. Despite its expanding burden, effective antiviral therapies remain unavailable, and vaccine access is limited. This talk will review the epidemiology, molecular biology, and clinical impact of CHIKV, followed by our laboratory’s efforts to develop countermeasures. We describe the development of an inactivated CHIKV vaccine candidate and a live-attenuated small-plaque variant carrying an E2-H232R mutation, which is highly attenuated in mouse models while retaining immunogenic potential. We also present a cell-based high-throughput screening platform using recombinant CHIKV expressing EGFP to identify inhibitors of viral replication. Screening of natural-product and drug-like compound libraries identified withaferin A, a steroidal lactone from Withania somnifera, which inhibits CHIKV replication by targeting the nsP2 protease and reducing viral RNA synthesis and infectious titers. In mice, withaferin A lowered viremia and prevented joint swelling. We further identified emetine, a repurposed alkaloid, as a potent CHIKV inhibitor that binds the nsP2 helicase, suppresses viral RNA synthesis, and protects mice even when administered 72 hours after infection. Together, these studies provide promising vaccine and antiviral candidates and illustrate how structure-guided and screening-based approaches can strengthen preparedness against re-emerging viral threats.

© 2026 Indian Academy of Sciences, Bengaluru.